标题
Genotype-driven therapeutic developments in Parkinson’s disease
作者
关键词
-
出版物
MOLECULAR MEDICINE
Volume 27, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-04-19
DOI
10.1186/s10020-021-00281-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities
- (2021) Jannik Prasuhn et al. Frontiers in Cell and Developmental Biology
- Lysosome and Inflammatory Defects in GBA1 ‐Mutant Astrocytes Are Normalized by LRRK2 Inhibition
- (2020) Anwesha Sanyal et al. MOVEMENT DISORDERS
- Clinical and Dopamine Transporter Imaging Characteristics of Leucine‐ Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study
- (2020) Tanya Simuni et al. MOVEMENT DISORDERS
- Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations
- (2020) Stephen Mullin et al. JAMA Neurology
- Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease
- (2020) Etienne C. Hirsch et al. MOVEMENT DISORDERS
- Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease
- (2020) Heather Wilson et al. MOVEMENT DISORDERS
- The effect of LRRK2 loss-of-function variants in humans
- (2020) Nicola Whiffin et al. NATURE MEDICINE
- α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
- (2020) Cecilia S. Lindestam Arlehamn et al. Nature Communications
- Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
- (2020) Ying Sun et al. EBioMedicine
- Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria
- (2020) Xiao-Yu Cheng et al. Translational Neurodegeneration
- Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson’s disease pathogenesis
- (2020) Stefanie Smolders et al. Acta Neuropathologica Communications
- Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism
- (2020) Max Borsche et al. BRAIN
- High-Resolution Dynamic 31P-MR Spectroscopic Imaging for Mapping Mitochondrial Function
- (2020) Bryan Clifford et al. IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
- GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes
- (2020) Andrea Greuel et al. MOVEMENT DISORDERS
- The Rostock International Parkinson's Disease ( ROPAD ) Study: Protocol and Initial Findings
- (2020) Volha Skrahina et al. MOVEMENT DISORDERS
- Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment
- (2020) Yoshiki Niimi et al. Journal of Parkinsons Disease
- Progress of pharmacological approaches in Parkinson's disease
- (2019) Kirsten E. Zeuner et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Brain cytochrome‐c‐oxidase as a marker of mitochondrial function: A pilot study in major depression using NIRS
- (2019) Lisa Holper et al. DEPRESSION AND ANXIETY
- Will genotype drive treatment options?
- (2019) Norbert Brüggemann et al. MOVEMENT DISORDERS
- Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
- (2019) Zhipeng Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
- (2019) B. R. Bloem et al. BMC Neurology
- SNCA rs11931074 polymorphism correlates with spontaneous brain activity and motor symptoms in Chinese patients with Parkinson’s disease
- (2019) Qian-Qian Si et al. JOURNAL OF NEURAL TRANSMISSION
- CSF and blood biomarkers for Parkinson's disease
- (2019) Lucilla Parnetti et al. LANCET NEUROLOGY
- Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
- (2019) Takuya Uehara et al. Scientific Reports
- Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an in vivo11C-BU99008 PET study
- (2019) Heather Wilson et al. BRAIN
- The genetic architecture of Parkinson's disease
- (2019) Cornelis Blauwendraat et al. LANCET NEUROLOGY
- Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
- (2019) Heather Wilson et al. LANCET NEUROLOGY
- Update of the MDS research criteria for prodromal Parkinson's disease
- (2019) Sebastian Heinzel et al. MOVEMENT DISORDERS
- Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
- (2019) Michael X. Henderson et al. Acta Neuropathologica Communications
- LRRK2 and GBA Variants Exert Distinct Influences on Parkinson’s Disease-Specific Metabolic Networks
- (2019) Katharina A Schindlbeck et al. CEREBRAL CORTEX
- CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease
- (2019) Yuanyuan Li et al. Journal of Neuroinflammation
- Emerging concepts of mitochondrial dysfunction in Parkinson’s disease progression: Pathogenic and therapeutic implications
- (2019) Linchi Rani et al. MITOCHONDRION
- Mechanism Underlying the Effectiveness of Deferiprone in Alleviating Parkinson’s Disease Symptoms
- (2018) Yingying Sun et al. ACS Chemical Neuroscience
- Genetic risk factors in Parkinson’s disease
- (2018) K. J. Billingsley et al. CELL AND TISSUE RESEARCH
- Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
- (2018) Jin-Sung Park et al. Current Neurology and Neuroscience Reports
- GBA-Associated Parkinson’s Disease and Other Synucleinopathies
- (2018) Ziv Gan-Or et al. Current Neurology and Neuroscience Reports
- The role of glucocerebrosidase in Parkinson disease pathogenesis
- (2018) Matthew E. Gegg et al. FEBS Journal
- The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study
- (2018) Shu-Ying Liu et al. LANCET NEUROLOGY
- Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson’s Disease
- (2018) Diana Alarcón-Arís et al. MOLECULAR THERAPY
- Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease
- (2018) Inga Peter et al. JAMA Neurology
- Progression in the LRRK2-Associated Parkinson Disease Population
- (2018) Rachel Saunders-Pullman et al. JAMA Neurology
- Dual-calibrated fMRI measurement of absolute cerebral metabolic rate of oxygen consumption and effective oxygen diffusivity
- (2018) M. Germuska et al. NEUROIMAGE
- Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review
- (2018) Joanne Trinh et al. MOVEMENT DISORDERS
- A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism
- (2018) Adam Book et al. Frontiers in Neurology
- Therapeutic approaches to target alpha-synuclein pathology
- (2017) Patrik Brundin et al. EXPERIMENTAL NEUROLOGY
- Nusinersen for the treatment of spinal muscular atrophy
- (2017) Claudia A. Chiriboga Expert Review of Neurotherapeutics
- A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
- (2017) Jérôme Stirnemann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases
- (2017) Gilles Bonvento et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies
- (2017) Daryl J Wile et al. LANCET NEUROLOGY
- Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature
- (2017) Susanne A. Schneider et al. MOVEMENT DISORDERS
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
- (2017) Shuchi Mittal et al. SCIENCE
- Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
- (2017) Anna Migdalska-Richards et al. SYNAPSE
- Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?
- (2017) Sara Redenšek et al. Frontiers in Aging Neuroscience
- Nusinersen for the treatment of spinal muscular atrophy
- (2017) Claudia A. Chiriboga Expert Review of Neurotherapeutics
- Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
- (2017) Brian Spencer et al. Acta Neuropathologica Communications
- Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice
- (2016) Anna Migdalska-Richards et al. ANNALS OF NEUROLOGY
- Survival and dementia inGBA-associated Parkinson's disease: The mutation matters
- (2016) Roberto Cilia et al. ANNALS OF NEUROLOGY
- Gene therapy targeting mitochondrial pathway in Parkinson’s disease
- (2016) Chi-Jing Choong et al. JOURNAL OF NEURAL TRANSMISSION
- How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
- (2016) Laura A. Volpicelli-Daley et al. JOURNAL OF NEUROCHEMISTRY
- Genetics of Parkinson's disease
- (2016) Christina M. Lill MOLECULAR AND CELLULAR PROBES
- First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers
- (2016) Dale B. Schenk et al. MOVEMENT DISORDERS
- Advances in markers of prodromal Parkinson disease
- (2016) Ronald B. Postuma et al. Nature Reviews Neurology
- Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
- (2016) Fernando Pagan et al. Journal of Parkinsons Disease
- Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease
- (2016) Marie Y. Davis et al. JAMA Neurology
- Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application
- (2016) Lingjia Xu et al. Parkinsons Disease
- Glucocerebrosidase activity in Parkinson’s disease with and withoutGBAmutations
- (2015) Roy N. Alcalay et al. BRAIN
- LRRK2 Pathways Leading to Neurodegeneration
- (2015) Mark R. Cookson Current Neurology and Neuroscience Reports
- Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
- (2015) Benjamin Dehay et al. LANCET NEUROLOGY
- Glucocerebrosidase and Parkinson disease: Recent advances
- (2015) Anthony H.V. Schapira MOLECULAR AND CELLULAR NEUROSCIENCE
- Neuropathology of α-synuclein propagation and braak hypothesis
- (2015) Heather McCann et al. MOVEMENT DISORDERS
- Alpha-synuclein propagation: New insights from animal models
- (2015) Benjamin Dehay et al. MOVEMENT DISORDERS
- Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
- (2015) Reina N. Fuji et al. Science Translational Medicine
- Development of targeted therapies for Parkinson’s disease and related synucleinopathies
- (2014) Edmund Sybertz et al. JOURNAL OF LIPID RESEARCH
- Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
- (2014) Veronica Lindström et al. NEUROBIOLOGY OF DISEASE
- Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson’s Disease
- (2014) Georgia S. Gaki et al. NEUROMOLECULAR MEDICINE
- The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
- (2014) Senthilkumar S. Karuppagounder et al. Scientific Reports
- α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
- (2014) Hien T. Tran et al. Cell Reports
- Genetics and genomics of Parkinson’s disease
- (2014) Michelle K Lin et al. Genome Medicine
- Parkinson disease: from pathology to molecular disease mechanisms
- (2013) David T. Dexter et al. FREE RADICAL BIOLOGY AND MEDICINE
- Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases
- (2013) Robert E. Boyd et al. JOURNAL OF MEDICINAL CHEMISTRY
- Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map
- (2013) Kazuhiro A. Fujita et al. MOLECULAR NEUROBIOLOGY
- Population-specific frequencies forLRRK2susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO-PD) consortium
- (2013) Michael G. Heckman et al. MOVEMENT DISORDERS
- Lysosomal impairment in Parkinson's disease
- (2013) Benjamin Dehay et al. MOVEMENT DISORDERS
- Biomarkers in Parkinson’s disease (recent update)
- (2013) Sushil Sharma et al. NEUROCHEMISTRY INTERNATIONAL
- Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations
- (2013) Andreas Puschmann PARKINSONISM & RELATED DISORDERS
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
- (2013) S. Pablo Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Next-Generation Phenotyping Using theParkinExample
- (2013) Anne Grünewald et al. JAMA Neurology
- Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele
- (2012) S. Anders et al. BRAIN
- Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences
- (2012) Nicole Exner et al. EMBO JOURNAL
- Lysosomal pathways to cell death and their therapeutic applications
- (2012) Maruša Hafner Česen et al. EXPERIMENTAL CELL RESEARCH
- The neuropathology of genetic Parkinson's disease
- (2012) Markos Poulopoulos et al. MOVEMENT DISORDERS
- Pathological -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
- (2012) K. C. Luk et al. SCIENCE
- mTOR: on target for novel therapeutic strategies in the nervous system
- (2012) Kenneth Maiese et al. TRENDS IN MOLECULAR MEDICINE
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
- (2011) Joseph R. Mazzulli et al. CELL
- Etiology and pathogenesis of Parkinson's disease
- (2011) Anthony H. Schapira et al. MOVEMENT DISORDERS
- Adaptive clinical trials in oncology
- (2011) Donald A. Berry Nature Reviews Clinical Oncology
- Use of ibuprofen and risk of Parkinson disease
- (2011) X. Gao et al. NEUROLOGY
- CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy
- (2011) S. P. Sardi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach
- (2010) Bart F.L. van Nuenen et al. MOVEMENT DISORDERS
- Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis
- (2010) J. J. Gagne et al. NEUROLOGY
- NSAID Use and the Risk of Parkinsonʼs Disease
- (2009) Ali Samii et al. DRUGS & AGING
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
- (2008) Daniel G Healy et al. LANCET NEUROLOGY
- Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype
- (2008) B.F.L. van Nuenen et al. NEUROLOGY
- Adaptive design methods in clinical trials – a review
- (2008) Shein-Chung Chow et al. Orphanet Journal of Rare Diseases
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search